Skip to main content
Getein Biotech, Inc logo

Getein Biotech, Inc — Investor Relations & Filings

Ticker · 603387 ISIN · CNE100002RR9 LEI · 6556006LO0FXVH4R6U94 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,163 across all filing types
Latest filing 2026-05-22 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 603387

About Getein Biotech, Inc

https://www.getein.com/

Getein Biotech, Inc. specializes in the research, development, manufacturing, and distribution of in vitro diagnostic reagents and instruments. The company provides a diverse portfolio of diagnostic solutions across multiple technology platforms, including Point-of-Care Testing (POCT), chemiluminescence immunoassay (CLIA), clinical chemistry, hematology, and molecular diagnostics. Its product offerings address various clinical fields such as cardiovascular health, inflammatory markers, infectious diseases, diabetes management, renal function, and fertility. Getein focuses on delivering rapid, accurate, and reliable diagnostic tools to healthcare facilities and laboratories. By leveraging integrated research and production capabilities, the company develops high-sensitivity assays and automated analytical systems designed to enhance clinical decision-making and improve patient care outcomes through efficient diagnostic workflows.

Recent filings

Filing Released Lang Actions
北京国枫（南京）律师事务所关于基蛋生物科技股份有限公司2025年年度股东会法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 85% confidence The document is a legal opinion letter from a law firm regarding the convening, procedures, and vote results of the company’s 2025 Annual General Meeting. It provides detailed voting tallies for each resolution, matching the definition of an official shareholder vote results announcement. Thus, it falls under Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-22 Chinese
基蛋生物：2025年年度股东会会议资料
AGM Information Classification · 95% confidence The document is the complete set of materials (meeting notice, agenda, proposals, reports, voting instructions) prepared for the company’s 2025 Annual General Meeting. It contains no financial statements themselves but rather the AGM presentation and meeting documentation. This aligns exactly with the definition of “AGM Information” (AGM-R).
2026-05-15 Chinese
基蛋生物：关于证券事务代表辞职的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the resignation of a securities affairs representative from the company. It details the resignation, the effective date, and the company's plan to appoint a replacement. There is no financial data, no report attached or referenced as being published, and no mention of financial results or regulatory certifications. This fits the category of Board/Management Information (MANG), as it concerns a change in a key company representative role.
2026-03-27 Chinese
基蛋生物：关于董事会秘书辞职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the resignation of the company's board secretary. It details the departure of a board/management official, the effective date, and the impact on the company. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings or other report types. This fits the category of Board/Management Information (MANG). The document length is short and focused solely on management change, confirming the classification.
2026-03-20 Chinese
基蛋生物：关于股票交易异常波动的公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the company's board regarding an abnormal stock price fluctuation over three consecutive trading days, confirming no undisclosed material information or major corporate actions that could explain the price movement. It includes risk warnings to investors and statements from the board about the absence of significant events or insider trading during the period. The content focuses on stock trading abnormality disclosure as per exchange rules, not on financial results, management changes, or other report types. The document length is short (1321 characters) and is a regulatory announcement about stock price behavior, fitting the category of Regulatory Filings (RNS) rather than a financial report or other specific filing type.
2026-03-18 Chinese
基蛋生物：关于2025年第三季度业绩网上说明会召开情况的公告
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement about a quarterly earnings online presentation held by the company, including Q&A with investors about the company's third quarter 2025 performance. It contains substantive discussion of financial and operational results for the third quarter, including sales figures, product performance, and strategic outlook. The document is not merely an announcement of a report publication but a detailed summary of the earnings call content. Therefore, it fits the category of an Interim / Quarterly Report (IR). The document length (4522 characters) is sufficient to contain substantive financial data and analysis, consistent with an IR filing.
2025-11-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.